CD38 and dilated cardiomyopathy: Since anti‐CD38 therapy is already available, such as isatuximab (SARCLISA®), which is approved for the treatment of adults with relapsed/refractory multiple myeloma, this study proposes that CD38 could be a possible therapeutic target in DMD, especially for one of its main features, namely the dilated cardiomyopathy.